Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 262 matching trials from the live ClinicalTrials.gov search.
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
GNS-3545, GNS-3545 Placebo
Drug
Lead sponsor
Genosco Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Terminated Phase 3 Interventional Results available

CleanUP IPF for the Pulmonary Trials Cooperative

NCT02759120
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Antimicrobial therapy: Co-trimoxazole or Doxycycline, No Intervention: Standard of Care
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 22 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
SAR156597, Placebo (for SAR156597)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Sacramento, California • Jacksonville, Florida • Chicago, Illinois + 7 more
Conditions
Asthma, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, IPF, COPD, Respiratory Disease
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
Not listed
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Colorado Springs, Colorado • Clearwater, Florida • Louisville, Kentucky + 2 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Ifetroban Sodium, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
20
States / cities
La Mesa, California • San Francisco, California • Farmington, Connecticut + 17 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Pamrevlumab, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
40 Years to 85 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
AZD5055, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Conditions
Idiopathic Pulmonary Fibrosis, Emphysema or COPD
Interventions
CD3/CD19 negative hematopoietic stem cells, Rituximab, Alemtuzumab, Fludarabine, Thiotepa, G-CSF, Hydroxyurea
Biological · Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Buloxibutid, Placebo
Drug
Lead sponsor
Vicore Pharma AB
Industry
Eligibility
40 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Redding, California • Sacramento, California + 19 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BI 765423, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Gainesville, Florida • Ocala, Florida + 11 more
Completed No phase listed Observational

Microaspiration in Pulmonary Fibrosis

NCT01150591
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
San Francisco, California
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Physical exercise training, Cognitive exercise training
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Multi-Disciplinary Patient Centered Rehab and Education
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Completed Phase 3 Interventional Results available

The Effect of N115 on Coughing in IPF Patients

NCT06037408
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
20mM sodium pyruvate nasal spray, Saline Placebo control nasal spray
Drug · Other
Lead sponsor
Cellular Sciences, inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Hialeah Gardens, Florida
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
QAX576, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
7
States / cities
Gainesville, Florida • Orlando, Florida • Boston, Massachusetts + 4 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
MTX-463, Placebo
Biological · Other
Lead sponsor
Mediar Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 19 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Interferon-gamma 1b
Drug
Lead sponsor
InterMune
Industry
Eligibility
20 Years to 79 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more
Conditions
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Lung Diseases, Interstitial
Interventions
hymecromone
Drug
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Interventions
Inhaled Nitric Oxide
Drug
Lead sponsor
Geno LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 7 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Retrospective observational study- no intervention to occur.
Other
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
Not listed
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Iowa City, Iowa • Boston, Massachusetts • St Louis, Missouri + 3 more
Conditions
Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2035
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
66 Years and older
Enrollment
1,798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Milton, Massachusetts
Conditions
Idiopathic Pulmonary Fibrosis, Lung Transplant; Complications
Interventions
Nintedanib, Placebo Oral Tablet
Drug
Lead sponsor
Temple University
Other
Eligibility
35 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania